ncRNA basic information
ncRNA ID:
MI0000268
ncRNA Database:
miRBase
ncRNA Name:
miR-34a
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
FOXP1
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00997 (APRD00185, DB05331, DB05847)
Drug Name:
Doxorubicin
Drug Method:
To identify biomarkers for cytotoxic response assessment, microRNAs (miRNAs) associated with doxorubicin sensitivity were determined by combining global miRNA expression profiling with systematic dose-response screens in 15 human DLBCL cell lines. One candidate, miR-34a, was tested in functional in vitro studies and in vivo in a retrospective clinical cohort. High expression of miR-34a was observed in cell lines sensitive to doxorubicin, and upregulation of miR-34a is documented here to increase doxorubicin sensitivity in in vitro lentiviral transduction assays. High expression of miR-34a had a prognostic impact using overall survival as outcome. With risk stratification of DLBCL samples based on resistance gene signatures (REGS), doxorubicin-responsive samples had statistically significant upregulated miR-34a expression. Classification of the DLBCL samples into subset-specific B cell-associated gene signatures (BAGS) revealed differentiation-specific expression of miR-34a. Our data further support FOXP1 as a target of miR-34a, suggesting that downregulation of FOXP1 may sensitize DLBCL cells to doxorubicin.
Drug Response:
sensitive
Cancer basic information
Cancer:
diffuse large B-cell lymphoma
Tissue/Cell:
cell line (DB, MC-116, NU-DHL-1, SU-DHL-4, SUDHL-5,FARAGE, HBL-1, OCI-Ly3,OCI-Ly7, OCI-Ly19, RIVA, SU-DHL-8, and U2932)
Other information
Title:
High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma
Journal:
Exp Hematol
Published:
2016
PubMed ID:
26854484